Market Overview

Benzinga's Top Upgrades, Downgrades For January 13, 2020

Share:

Upgrades

  • For 3D Systems Corp (NYSE: DDD), Craig-Hallum upgraded the stock from Hold to Buy. For the third quarter, 3D Systems had an EPS of ($0.04), compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $14.50 and a 52-week-low of $6.46. 3D Systems's stock last closed at $9.99 per share.
  • Loop Capital changed the rating for Ryder System Inc (NYSE: R) from Hold to Buy. In the third quarter, Ryder System showed an EPS of $1.52, compared to $1.64 from the year-ago quarter. The stock has a 52-week-high of $67.65 and a 52-week-low of $44.90. Ryder System's stock last closed at $53.12 per share.
  • For Nuance Communications Inc (NASDAQ: NUAN), Morgan Stanley upgraded the stock from Equal-Weight to Overweight. For the fourth quarter, Nuance Communications had an EPS of $0.33, compared to year-ago quarter EPS of $0.38. The stock has a 52-week-high of $18.53 and a 52-week-low of $12.48. Nuance Communications's stock last closed at $18.40 per share.
  • For TerraForm Power Inc (NASDAQ: TERP), BMO Capital upgraded the stock from Market Perform to Outperform. In the third quarter, TerraForm Power showed an EPS of ($0.26), compared to ($0.16) from the year-ago quarter. The stock has a 52-week-high of $18.48 and a 52-week-low of $11.25. TerraForm Power's stock last closed at $15.60 per share.
  • For Saratoga Investment Corp (NYSE: SAR), Ladenburg Thalmann upgraded the stock from Neutral to Buy. For the third quarter, Saratoga Investment had an EPS of $0.61, compared to year-ago quarter EPS of $0.65. The stock has a 52-week-high of $26.39 and a 52-week-low of $21.22. Saratoga Investment's stock last closed at $26.75 per share.
  • Evercore ISI Group upgraded the stock for Teradyne Inc (NASDAQ: TER) from In-Line to Outperform. In the third quarter, Teradyne showed an EPS of $0.77, compared to $0.71 from the year-ago quarter. The stock has a 52-week-high of $69.90 and a 52-week-low of $30.84. Teradyne's stock last closed at $67.93 per share.
  • Credit Suisse changed the rating for Hexcel Corp (NYSE: HXL) from Neutral to Outperform. Hexcel earned $0.90 in the third quarter, compared to $0.80 in the year-ago quarter. The stock has a 52-week-high of $87.00 and a 52-week-low of $59.25. Hexcel's stock last closed at $72.91 per share.
  • For NVIDIA Corp (NASDAQ: NVDA), Needham upgraded the stock from Underperform to Hold. In the third quarter, NVIDIA showed an EPS of $1.78, compared to $1.84 from the year-ago quarter. The stock has a 52-week-high of $245.93 and a 52-week-low of $131.00. NVIDIA's stock last closed at $244.32 per share.
  • Credit Suisse upgraded the stock for DTE Energy Co (NYSE: DTE) from Underperform to Neutral. DTE Energy earned $1.91 in the third quarter, compared to $2.13 in the year-ago quarter. The stock has a 52-week-high of $134.37 and a 52-week-low of $108.52. DTE Energy's stock last closed at $128.88 per share.
  •  

Downgrades

  • Morgan Stanley changed the rating for Cimarex Energy Co (NYSE: XEC) from Overweight to Equal-Weight. In the third quarter, Cimarex Energy showed an EPS of $0.91, compared to $1.99 from the year-ago quarter. The stock has a 52-week-high of $77.10 and a 52-week-low of $37.19. Cimarex Energy's stock last closed at $54.01 per share.

 

 

Initiations

  • With a rating of Outperform, Northland initiated coverage on Constellium SE (NYSE: CSTM). The price target is set at $19.00 for Constellium. Constellium earned $0.00 in the third quarter, compared to $0.19 in the year-ago quarter. The stock has a 52-week-high of $15.10 and a 52-week-low of $7.42. Constellium's stock last closed at $13.29 per share.
  • SunTrust Robinson Humphrey initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO) with a Buy rating. The price target for Sutro Biopharma is set at $18.00. In the third quarter, Sutro Biopharma showed an EPS of ($0.56), compared to ($21.26) from the year-ago quarter. The stock has a 52-week-high of $12.75 and a 52-week-low of $7.69. Sutro Biopharma's stock last closed at $12.00 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on NextCure Inc (NASDAQ: NXTC). The price target is set at $78.00 for NextCure. Interestingly, in the third quarter, NextCure's EPS was ($0.37). The stock has a 52-week-high of $109.00 and a 52-week-low of $13.86. NextCure's stock last closed at $56.70 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Genmab A/S (NASDAQ: GMAB). The price target is set at $28.00 for Genmab. Genmab earned $1.22 in the third quarter, compared to $0.43 in the year-ago quarter. The stock has a 52-week-high of $24.50 and a 52-week-low of $14.48. Genmab's stock last closed at $22.70 per share.
  • SunTrust Robinson Humphrey initiated coverage on Forty Seven Inc (NASDAQ: FTSV) with a Buy rating. The price target for Forty Seven is set at $55.00. In the third quarter, Forty Seven showed an EPS of ($0.38), compared to ($0.71) from the year-ago quarter. The stock has a 52-week-high of $45.39 and a 52-week-low of $5.53. Forty Seven's stock last closed at $35.28 per share.
  • JP Morgan initiated coverage on Forestar Group Inc (NYSE: FOR) with a Neutral rating. The price target for Forestar is set at $22.00. Interestingly, in the fourth quarter, Forestar's EPS was $0.30. The stock has a 52-week-high of $23.00 and a 52-week-low of $13.46. Forestar's stock last closed at $19.92 per share.
  • SunTrust Robinson Humphrey initiated coverage on Exelixis Inc (NASDAQ: EXEL) with a Buy rating. The price target for Exelixis is set at $31.00. In the third quarter, Exelixis showed an EPS of $0.34, compared to $0.41 from the year-ago quarter. The stock has a 52-week-high of $25.31 and a 52-week-low of $15.02. Exelixis's stock last closed at $18.32 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Deciphera Pharmaceuticals Inc (NASDAQ: DCPH). The price target is set at $77.00 for Deciphera Pharmaceuticals. For the third quarter, Deciphera Pharmaceuticals had an EPS of ($1.28), compared to year-ago quarter EPS of ($0.65). The stock has a 52-week-high of $70.00 and a 52-week-low of $19.88. Deciphera Pharmaceuticals's stock last closed at $62.52 per share.
  • With a rating of Neutral, JP Morgan initiated coverage on Albany International Corp (NYSE: AIN). The price target is set at $76.00 for Albany International. For the third quarter, Albany International had an EPS of $1.17, compared to year-ago quarter EPS of $0.85. The stock has a 52-week-high of $92.05 and a 52-week-low of $65.23. Albany International's stock last closed at $75.01 per share.
  • With a rating of Buy, H.C. Wainwright initiated coverage on CEL-SCI Corp (AMEX: CVM). The price target is set at $18.00 for CEL-SCI. For the fourth quarter, CEL-SCI had an EPS of ($0.14), compared to year-ago quarter EPS of ($0.70). The stock has a 52-week-high of $9.93 and a 52-week-low of $2.37. CEL-SCI's stock last closed at $7.77 per share.

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Intraday Update Analyst Ratings

 

Related Articles (AIN + CSTM)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com